The Influence of Drug-Eluting Beads Transarterial Chemoembolization on Serum Levels of Soluble Programmed Cell Death Protein-1 in Advanced Hepatocellular Carcinoma Patients

Figures & data

Table 1 Comparison of sPD-1 According to Clinical Characteristics of HCC Patients

	No.	Mean sPD-1	P value
Sex			0.421
Male	36	279.37±191.94
Female	8	339.73±180.35
Age			0.798
≥60yrs	15	280.00±162.35
<60yrs	29	295.70±204.38
BCLC stage			0.551
A stage	9	350.74±145.30
B stage	8	291.46±136.55
C stage	27	269.88±214.60
Portal venous invasion			0.909
Yes	23	293.53±222.75
No	21	286.86±149.82
Child-Pugh score			0.846
A	31	286.70±182.52
B	13	299.03±212.17
AFP (ng/mL)			0.405
≤20	17	320.72±156.27
>20	27	271.22±207.98
HBV-DNA(IU/mL)			0.574
<500	20	308.18±149.87
≥500	24	275.48±218.95
Tumor location			0.958
Monolobar	26	291.62±182.31
Bilobar	18	288.51±204.35
Up to 7 criteria			0.191
≤7	9	364.44±184.78
>7	35	271.29±188.32

Figure 1 Comparison of the initial sPD-1 levels between HCC patients and normal controls. A significant difference was observed between the two groups (P = 0.031).

Figure 2 Comparison of the initial sPD-L1 levels among different BCLC staging categories. No significant differences were detected (P = 0.551).

Figure 3 Fluctuation of sPD-1 levels in seven HCC patients during the course of D-TACE treatment. The sPD-1 level on 3 days post-D-TACE was lower than that before D-TACE (P = 0.032), and the sPD-1 level on 30 days post-D-TACE was higher than that on 3 and 7 days post-D-TACE (P = 0.039, P = 0.002). However, there were no significant differences between sPD-1 levels on 3 and 7 days post-D-TACE (P = 0.541) and between 1 day before D-TACE and 30 days after D-TACE (P = 0.920).

Figure 4 Comparison of sPD-1 levels on 3 days after D-TACE between 100–300µm and 300–500µm Callispheres beads. No significant differences were observed (P = 0.914).

Figure 5 Comparison of sPD-1 levels on 7 days after D-TACE between 100–300µm and 300–500µm Callispheres beads. The results showed significant differences (P = 0.017).

Figure 6 Comparison of the initial sPD-1 levels among different curative effect groups 30 days after D-TACE based on mRECIST criteria. No significant differences were found (P = 0.707).